Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression
Impact of Alginate Overproduction on P. aeruginosa LPS O Antigen Expression
批准号:
9317789
负责人:
Joanna B Goldberg
金额:
$19.25万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-19 至 2018-12-31
关键词:
AgeAlginatesAntibiotic ResistanceBacteriaBronchiectasisChronicClinicalCystic FibrosisDevelopmentEnvironmentGenesGeneticGenetic TranscriptionGenotypeGoalsGram-Negative BacteriaImmune responseInfectionIntegration Host FactorsLaboratoriesLengthLifeLife ExpectancyLinkLipopolysaccharidesLungMolecularMonitorO AntigensPatient IsolatorsPatientsPhenotypePolysaccharidesPopulationProcessPseudomonas aeruginosaPulmonary FibrosisRepressionResearch Project GrantsRespiratory Tract InfectionsSignal TransductionTherapeutic Interventioncystic fibrosis patientsimprovedmouse modelmucoidpathogenpreventrespiratorytargeted treatment
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT.
Pseudomonas aeruginosa, a Gram-negative bacterium, is an important opportunistic pathogen and the
leading cause of chronic life-threatening lung infections in cystic fibrosis (CF) patients. P. aeruginosa is
naturally antibiotic resistant and infections with this bacterium are notoriously difficult to treat. About 70% of
CF patients are infected with P. aeruginosa by age 18 and the mean life expectancy is less than 40 years. A
better understanding of how this bacterium evolves to cause these chronic respiratory infections is needed.
Numerous phenotypic changes take place as P. aeruginosa transitions from the environment to causing
life-shortening chronic CF lung infections. The emergence of isolates with a mucoid phenotype, due to the
overproduction of the exopolysaccharide alginate is the most conspicuous; the isolation of mucoid strains is a
prognosticator of clinical decline in these patients. Mucoid strains also have an additional less obvious
polysaccharide alteration: these strains are generally lack lipopolysaccharide (LPS) O antigen, a phenotype
referred to as “LPS-rough”. Interestingly, this same conversion to a mucoid, LPS-rough form is prominent in P.
aeruginosa isolates from patients with non-CF chronic bronchiectasis. In rare mucoid strains that do express
LPS O antigen, different lengths of LPS O antigen are expressed compared to non-mucoid LPS-smooth
strains: while LPS isolated from non-mucoid strains includes both long and very long O antigen, LPS isolated
from mucoid strains shows decreased expression of very long O antigen but the same expression of long O
antigen, which we suggest represents a transition state between the initial- and chronic-infecting forms.
The goal of this 2-year Exploratory/Developmental Research Grant is to determine how mucoidy and
loss of O antigen (as well as other genotypes) emerge during chronic colonization and how the bacteria and
host respond to these infections. In Specific Aim 1, we will utilize the laboratory strain PAO1 and its mucoid
derivative, PDO300, in a newly described murine model of chronic respiratory colonization and will follow the
phenotypes and genotypes of the strains emerging and evolving during colonization as well as the bacterial
and host response to infection. In Specific Aim 2, we will take a molecular approach to identify the genetic
regulatory mechanisms controlling very long O antigen in a mucoid LPS-smooth strain and assess how
alginate represses very long O antigen. The discovery of factors involved in the repression wzz2 (the gene
which encodes the very long O antigen chain length regulator) will provide the relevant targets for therapeutic
intervention. If we can inhibit the repression wzz2, this may set up a situation where the bacteria cannot
maintain the mucoid phenotype and therefore would not be shielded from the innate host immune response or
evolve into a chronic-colonizing form. The long-term goal of these studies will be to identify bacterial factors
that can be targeted to inhibit chronic lung infection and host factors that can increase bacterial clearance and
therefore improve the lives of CF patients.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Monoclonal Antibody to Combat Pseudomonas Aeruginosa
-
批准号:10674274
-
项目类别:
-
资助金额:$102.18万
-
财政年份:2023
-
负责人:Joanna B Goldberg
-
依托单位:
Pyocins as antibacterials to treat Pseudomonas aeruginosa infections
-
批准号:10727705
-
项目类别:
-
资助金额:$21.99万
-
财政年份:2023
-
负责人:Joanna B Goldberg
-
依托单位:
Mechanisms of Staphylococcus aureus and Pseudomonas aeruginosa Co-existence in CF
-
批准号:10078252
-
项目类别:
-
资助金额:$22.95万
-
财政年份:2020
-
负责人:Joanna B Goldberg
-
依托单位:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
-
批准号:8638629
-
项目类别:
-
资助金额:$23.19万
-
财政年份:2014
-
负责人:Joanna B Goldberg
-
依托单位:
Mechanism of Phosphorylcholination of EF-Tu on Pseudomonas aeruginosa
-
批准号:8912974
-
项目类别:
-
资助金额:$19.29万
-
财政年份:2014
-
负责人:Joanna B Goldberg
-
依托单位:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
-
批准号:8583633
-
项目类别:
-
资助金额:$23.39万
-
财政年份:2013
-
负责人:Joanna B Goldberg
-
依托单位:
Virulence Determinants for Host Tropism in the Burkholderia cepacia complex
-
批准号:8665382
-
项目类别:
-
资助金额:$19.57万
-
财政年份:2013
-
负责人:Joanna B Goldberg
-
依托单位:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
-
批准号:8488407
-
项目类别:
-
资助金额:$22.0万
-
财政年份:2012
-
负责人:Joanna B Goldberg
-
依托单位:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
-
批准号:8385961
-
项目类别:
-
资助金额:$8.88万
-
财政年份:2012
-
负责人:Joanna B Goldberg
-
依托单位:
Purine biosynthesis as a therapeutic target for Helicobacter pylori infection
-
批准号:8635527
-
项目类别:
-
资助金额:$10.83万
-
财政年份:2012
-
负责人:Joanna B Goldberg
-
依托单位:
Role of Burkholderia Cenocepacia Adhesin, AdhA, in Cystic Fibrosis Infections
-
批准号:7754868
-
项目类别:
-
资助金额:$22.22万
-
财政年份:2009
-
负责人:Joanna B Goldberg
-
依托单位:
Novel Recombinant Vaccines to Protect Against Burkholderia Infections
-
批准号:7247611
-
项目类别:
-
资助金额:$19.45万
-
财政年份:2007
-
负责人:Joanna B Goldberg
-
依托单位:
Novel Recombinant Vaccines to Protect Against Burkholderia Infections
-
批准号:7484958
-
项目类别:
-
资助金额:$22.64万
-
财政年份:2007
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:7629589
-
项目类别:
-
资助金额:$35.89万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:7150146
-
项目类别:
-
资助金额:$37.72万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:8147892
-
项目类别:
-
资助金额:$13.47万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:7236052
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:7432599
-
项目类别:
-
资助金额:$35.9万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
-
批准号:7881523
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2006
-
负责人:Joanna B Goldberg
-
依托单位:
Pseudomonas aeruginasa LPS: A Post-Genomic Analysis
-
批准号:6687621
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2003
-
负责人:Joanna B Goldberg
-
依托单位:
海外基金